Patent ID: 7943640

Claim:
A method of treating a TGF-β stimulated proliferative disorder, in a patient in need thereof, comprising administering to said patient a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein Pg is hydrogen, alkyl, or a nitrogen protecting group; n is an integer from 0 to 3; each R 1 substituent is independently selected from the group consisting of —R 2 , -T-R 2 , and —V-T-R 2 ; each R 2 is independently selected from the group consisting of C 1-3 aliphatic, hydroxy, —N(R 3 ) 2 , halo, cyano, —OR 4 , —C(O)R 4 , —CO 2 R 4 , —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 3 )C(O)R 4 , —N(R 3 )CO 2 R 4 , —N(R 3 )SO 2 R 4 , —C(O)N(R 3 ) 2 , —SO 2 N(R 3 ) 2 , —N(R 3 )C(O)N(R 3 ) 2 , —OC(O)R 4 , phenyl which is optionally substituted with 1-3 R 5 , 5-6 membered heterocyclyl which is optionally substituted with 1-3 R 5 , and 5-6 membered heteroaryl which is optionally substituted with 1-3 R 5 ; each T is independently C 1-5 alkylidene that is optionally interrupted by —O—, —C(O)—, —S—, —S(O)—, —S(O) 2 —, or —N(R 3 )—; each V is independently selected from the group consisting of —O—, —S—, —S(O)—, —S(O) 2 —, —C(O)—, —N(R 3 )—, —N(R 3 )C(O)—, or —N(R 3 )C(O) 2 —, —N(R 3 )S(O) 2 —, —C(O)N(R 3 )—, —S(O) 2 N(R 3 )—, —N(R 3 )C(O)N(R 3 )—, and —OC(O)—; each R 3 is independently selected from the group consisting of hydrogen, C 1-6 aliphatic, —C(O)R 4 , —C(O) 2 R 4 , and —SO 2 R 4 , or two R 3 on the same nitrogen together with their intervening nitrogen form a 5-6 membered heterocyclyl or heteroaryl ring having 1-3 ring heteroatoms selected from nitrogen, oxygen or sulfur; each R 4 is independently selected from the group consisting of C 1-6 aliphatic, phenyl or a 5-6 membered heteroaryl or heterocyclyl having 1-3 ring heteroatoms selected from nitrogen, oxygen or sulfur; R 8 is selected from the group consisting of: (a) aryl, heteroaryl, and cycloalkyl, each of which is optionally substituted with 1-3 R 5 , and (b) alkyl; each R 5 is independently selected from the group consisting of C 1-6 aliphatic, halo, —OH, —N(R 3 ) 2 , cyano, —C(O)R 4 , —CO 2 R 4 , —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 3 )C(O)R 4 , —N(R 3 )CO 2 R 4 , —N(R 3 )SO 2 R 4 , —C(O)N(R 3 ) 2 , —SO 2 N(R 3 ) 2 , —N(R 3 )C(O)N(R 3 ) 2 , —OC(O)R 4 , —OC(O)N(R 3 ) 2 , phenyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl, or two adjacent R 5 on an aryl, cycloalkyl, or heteroaryl ring are taken together with their intervening atoms to form a 5-6 membered fused ring having 0-2 heteroatoms selected from nitrogen, oxygen or sulfur; each R 6 is independently selected from the group consisting of hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 monoalkylamino and C 1-4 dialkylamino; and R 7 is selected from the group consisting of hydrogen, halo, —OH, —N(R 3 ) 2 , cyano, —OR 4 , —C(O)R 4 , —CO 2 R 4 , —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —N(R) 3 )C(O)R 4 , —N(R 3 )CO 2 R 4 , —N(R 3 )SO 2 R 4 , —C(O)N(R 3 ) 2 , —SO 2 N(R 3 ) 2 , —N(R 3 )C(O)N(R 3 ) 2 , and —OC(O)R 4 .